Overview: C1q Binding Immune Complex TestIntroduction: The C1q Binding Immune Complex Test detects immune complexes via C1q binding to diagnose autoimmune diseases, causing joint pain or fatigue. Aligned with 2023 ACR guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune conditions.
Other Names: C1q Immune Complex Assay, Immune Complex Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Immune complex testing began in the 1970s with autoimmune research. C1q binding assays improved in the 1990s, enhancing diagnostic precision.
Purpose: Detects immune complexes to diagnose autoimmune diseases, guides treatment, and evaluates patients with joint pain or fatigue.
Test Parameters: 1. Immune Complex C1q
Pretest Condition: No fasting required. Collect serum at any time. Report history of joint pain, fatigue, or autoimmune diseases.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document joint pain, fatigue, or autoimmune diseases (e.g., lupus, rheumatoid arthritis). Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, autoimmune implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses immunoassays to detect C1q-bound immune complexes. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for autoimmune assessment.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Recent infections may cause false positives.
Clinical Significance: Elevated immune complexes suggest autoimmune diseases, guiding immunosuppressive therapy. Normal levels may require further autoimmune testing.
Specialist Consultation: Consult a rheumatologist for result interpretation and treatment planning.
Additional Supporting Tests: ANA, RF, or complement levels (C3, C4) to assess autoimmune diseases.
Test Limitations: Not specific to one autoimmune disease; clinical correlation is needed. False positives may occur with infections.
References: ACR Autoimmune Guidelines, 2023; Arthritis & Rheumatology, Agnello V, 2022.
